Ascendis Pharma AS Overview
Industry: Biotechnology
Sector: Healthcare
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 /? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; Tran Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Ascendis Pharma AS into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
No latest earnings report cached yet
Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns
Headline from Yahoo Finance: Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns.
BofA raises Ascendis Pharma stock price target on revenue outlook By Investing.com
Headline from Investing.com Canada: BofA raises Ascendis Pharma stock price target on revenue outlook By Investing.com.
BofA raises Ascendis Pharma stock price target on revenue outlook
Headline from Investing.com: BofA raises Ascendis Pharma stock price target on revenue outlook.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.